CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Ipilimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03873818
NCT03873818Phase 2Completed
CompareCT.gov

A Phase II Study of Open Label Low Dose Ipilimumab in Combination With Pembrolizumab in Metastatic Melanoma Patients With Brain Metastases

M.D. Anderson Cancer Center·interventional·Posted Mar 13, 2019·Updated Jan 9, 2026

In Brief

A Phase 2 clinical trial evaluating Ipilimumab and Pembrolizumab for Clinical Stage IV Cutaneous Melanoma AJCC v8 and 3 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 13, 2019
Enrollment StartFeb 21, 2019
Primary CompletionAug 21, 2025
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 7.3 years ago

Interventions

Ipilimumabbiological

Given IV

Pembrolizumabbiological

Given IV